The headline you probably saw. In May 2025, a wave of coverage reported that vitamin D supplements "may slow biological aging." The stories traced back to a real randomized controlled trial, published in The American Journal of Clinical Nutrition, finding that people taking vitamin D lost less telomere length over four years than people taking placebo. Telomeres are the protective caps at the ends of chromosomes, and they shorten as we get older.
The finding is real. the interpretation is not. This is worth walking through carefully, because it is an unusually clean example of how a modest laboratory result becomes an anti-aging headline — and because, in this particular case, we do not have to speculate about whether the marker means anything. The same trial already measured whether people actually got sick, and the answer was no.
What the study did. Researchers took 1,031 participants from VITAL, a large trial that randomly assigned nearly 26,000 adults to 2,000 IU of vitamin D3 daily, 1 gram of marine omega-3 daily, both, or placebo. In this sub-study they measured telomere length in white blood cells at the start, at two years and at four years. Average age was 65.
What it found. At four years, the vitamin D group had telomeres about 140 base pairs longer than placebo — a difference of 0.14 kilobases, with a 95% confidence interval of 0.007 to 0.27 and a p-value of 0.039. At two years there was no significant difference at all. The omega-3 group showed no effect at either timepoint.
Read those numbers again, because they are doing a lot of work. The lower edge of the confidence interval is 0.007 kilobases — seven base pairs. That is about as close to zero as a "positive" result can come. The effect appeared at only one of the two timepoints measured, the analysis was not corrected for multiple comparisons, and 37% of participants were missing at year four, the single timepoint that produced the result. For scale, the difference amounts to roughly one-tenth of the normal variation between two people.
Where "three years of aging" came from. Almost every news story repeated a figure: the vitamin D group looked about three years younger. That number is not a measured outcome. It is the authors' own back-of-the-envelope conversion, dividing their 140 base pairs by an average annual telomere loss taken from a single unrelated cohort. It assumes telomere shortening is a steady clock and that preserving base pairs is the same thing as preserving youth. Neither is established.
The measurement method matters here. Telomere length was measured by qPCR, the cheapest and least reproducible of the available techniques. Telomere researchers have documented the problem repeatedly: qPCR agrees well with the gold-standard method when comparing people at a single moment, but for measuring change over time — precisely what this study did — the correlation drops to about 0.48. A blinded ten-laboratory comparison found variation above 20% between labs for qPCR versus around 10% for the reference methods. The paper reports no measurement-error statistics of its own, which is a notable gap when the entire conclusion rests on 140 base pairs.
Now the part the coverage left out. VITAL was not a small trial, and it did measure whether vitamin D keeps people healthy. In the full 25,871 participants, over a median 5.3 years, vitamin D did not reduce invasive cancer (hazard ratio 0.96, 95% CI 0.88–1.06), did not reduce major cardiovascular events (HR 0.97, 0.85–1.12), and did not reduce death from any cause (HR 0.99, 0.87–1.12). Separate analyses of the same trial found no effect on frailty, no effect on cognitive decline, no effect on fractures (HR 0.98 for total fractures), and no effect on depression.
So the claim reduces to this: a biomarker of aging moved slightly, while essentially every real consequence of aging that the trial measured did not. When a surrogate marker and the outcomes it is supposed to predict disagree inside the same trial, that is evidence against the marker, not evidence for the treatment.
There is also a problem with the premise. The phrase "longer telomeres, less aging" assumes longer is simply better. Genetic studies complicate that considerably. A Mendelian randomization analysis spanning 35 cancers and more than 420,000 cases found that people genetically predisposed to longer telomeres had substantially higher risk of several cancers — roughly five times the risk of glioma, three times the risk of lung adenocarcinoma, and nearly double the risk of melanoma — while having lower risk of coronary heart disease. Longer telomeres let cells keep dividing. That protects tissue from wearing out, and it is also what a tumor needs. It is a trade-off, not a free win.
What specialists say about the size of it. Mary Armanios, who directs the Telomere Center at Johns Hopkins, has commented publicly on this study: telomere length matters for aging mainly at the extremes, most people sit within a wide normal range, and a 140-base-pair difference falls inside ordinary human variation. She also flags qPCR as the least reproducible of the methods available.
One more honest detail. The paper's abstract describes the telomere outcome as pre-specified. Its own limitations section describes the work as a post hoc analysis of a trial not designed to test this question. The sub-study was registered in 2020, after the parent trial's follow-up was complete.
What VITAL did show. In fairness to the trial, it produced one genuine clinical finding: vitamin D reduced incident autoimmune disease by about 22% (HR 0.78, 95% CI 0.61–0.99) over five years, published in The BMJ. That is a real randomized result on a real health outcome. It has nothing to do with aging, and it received a fraction of the attention.
What this changes for you: nothing. Vitamin D is worth paying attention to for reasons that have not changed — correcting genuine deficiency, which is common at northern latitudes through the winter, supports bone and muscle health and is the basis for the intakes health agencies recommend. That case stands on its own. It is not strengthened by this study, and nobody should start taking vitamin D, or raise their dose, in order to lengthen their telomeres. See our vitamin D guide for what the evidence actually supports.
Bottom line. A carefully conducted sub-study found a small, statistically borderline difference in telomere length after four years of vitamin D, measured with the least reliable available assay, in a trial that found no effect on cancer, heart disease, death, frailty, cognition, fractures or depression. "Vitamin D slows biological aging" is a headline the data cannot carry.